Unlock your academic potential and expand your network by joining us!

institution avatar image

Institut de Neurophysiopathologie

Facility
526 Publications
5 Members

Basic Info

Members
Total: 5 members
Latest Publications
Journal Article
Infectious Disorders - Drug Targets
Published: 01 February 2025 in Infectious Disorders - Drug Targets
ACS Style

Julien Giacomoni; Jean-Marc Sabatier. Vitamin D and Mitochondrial Activity Preservation in COVID-19. Infectious Disorders - Drug Targets 2025, 25, 1 -3.

AMA Style

Julien Giacomoni, Jean-Marc Sabatier. Vitamin D and Mitochondrial Activity Preservation in COVID-19. Infectious Disorders - Drug Targets. 2025; 25 (1):1-3.

Chicago/Turabian Style

Julien Giacomoni; Jean-Marc Sabatier. 2025. "Vitamin D and Mitochondrial Activity Preservation in COVID-19." Infectious Disorders - Drug Targets 25, no. 1: 1-3.

Journal Article
Infectious Disorders - Drug Targets
Published: 01 February 2025 in Infectious Disorders - Drug Targets
ACS Style

Julien Giacomoni; Jean-Marc Sabatier. Renin-Angiotensin System Dysregulation: ADAM17 Activation Consequences Related to SARS-CoV-2. Infectious Disorders - Drug Targets 2025, 25, 1 -2.

AMA Style

Julien Giacomoni, Jean-Marc Sabatier. Renin-Angiotensin System Dysregulation: ADAM17 Activation Consequences Related to SARS-CoV-2. Infectious Disorders - Drug Targets. 2025; 25 (1):1-2.

Chicago/Turabian Style

Julien Giacomoni; Jean-Marc Sabatier. 2025. "Renin-Angiotensin System Dysregulation: ADAM17 Activation Consequences Related to SARS-CoV-2." Infectious Disorders - Drug Targets 25, no. 1: 1-2.

Journal Article
International Journal of Molecular Sciences
Published: 02 November 2024 in International Journal of Molecular Sciences

Growing evidence has unveiled the pathological significance of Tau in many cancers, including the most aggressive and lethal brain tumor glioblastoma multiform (GBM). In this regard, we have recently examined the structure–activity relationship of a new series of seventeen 2-aminothiazole-fused to flavonoid hybrid compounds (TZF) on Tau-overexpressing GBM cells. Here, we evaluated the anticancer activities of the two lead compounds 2 and 9 using multi-cellular spheroids (MCSs) which represent an easy 3D human cell model to mimic GBM organization, physical constraints and drug penetration. The two compounds reduced cell evasion from spheroids up to three times, especially for Tau-expressing cells. As a first step towards a therapeutic approach, we quantified the effects of these compounds on MCS growth using two complementary protocols: single and repeated treatments. A single injection with compound 9 slowed down the growth of MCSs formed with U87 shCTRL cells by 40% at 10 µM. More interestingly, multiple treatment with compound 9 slowed the growth of U87 shCTRL spheroids by 40% at a concentration of 5 µM, supporting the increased bioavailability of compound 9 within MCSs. In conclusion, compound 9 deserves particular attention as promising candidate for specifically targeting Tau-expressing cancers such as GBM.

ACS Style

Emmanuelle T. Relave; Rayane Hedna; Attilio Di Maio; François Devred; Hervé Kovacic; Maxime Robin; Gilles Breuzard. Therapeutic Contribution of Tau-Binding Thiazoloflavonoid Hybrid Derivatives Against Glioblastoma Using Pharmacological Approach in 3D Spheroids. International Journal of Molecular Sciences 2024, 25, 11785 .

AMA Style

Emmanuelle T. Relave, Rayane Hedna, Attilio Di Maio, François Devred, Hervé Kovacic, Maxime Robin, Gilles Breuzard. Therapeutic Contribution of Tau-Binding Thiazoloflavonoid Hybrid Derivatives Against Glioblastoma Using Pharmacological Approach in 3D Spheroids. International Journal of Molecular Sciences. 2024; 25 (21):11785.

Chicago/Turabian Style

Emmanuelle T. Relave; Rayane Hedna; Attilio Di Maio; François Devred; Hervé Kovacic; Maxime Robin; Gilles Breuzard. 2024. "Therapeutic Contribution of Tau-Binding Thiazoloflavonoid Hybrid Derivatives Against Glioblastoma Using Pharmacological Approach in 3D Spheroids." International Journal of Molecular Sciences 25, no. 21: 11785.

View all